Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients
Authors:
- Xiang ZhongXZXiang Zhong
- Zhan-Hong ChenZCZhan-Hong Chen
- Yan-Fang XingYXYan-Fang Xing
- Dong-Hao WuDWDong-Hao Wu
- Jie ChenJCJie Chen
- Xiao-Kun MaXMXiao-Kun Ma
- Qu LinQLQu Lin
- Jing-Yun WenJWJing-Yun Wen
- Li WeiLWLi Wei
- Tian-Tian WangTWTian-Tian Wang
- Dan-Yun RuanDRDan-Yun Ruan
Open Access
- 18 December 2014
- journal article
- research article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (22) , 9635-9641
Abstract
Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients Hepatitis B virus;hepatocellular carcinoma;transcatheter arterial chemoembolization;prognostic analysis; Background: This retrospective study was aimed to investigate the efficacy of prophylactic agents in hepatocellular carcinoma (HCC) patients receiving TACE and compare the difference between lamivudine and entecavir. Materials and Methods: A consecutive series of 203 HBV-related HCC patients receiving TACE were analyzed including 91 patients given prophylactic agents. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 IU/ml higher than the nadir level, hepatitis flares due to HBV reactivation and progression free survival (PFS) were the main endpoints. Results: Some 48 (69.6%) reached virologic response. Prophylaxis significantly reduced virologic events (8.8% vs 58.0%, p=0.000) and hepatitis flares (1.1% vs 13.4%, p=0.001). Patients presenting undetectable HBV DNA levels displayed a significantly improved PFS as compared to those who never achieved undetectable HBV DNA. Prophylaxis and e-antigen positivity were the only significant variables associated with virologic events. In addition, prophylaxis was the only independent protective factor for hepatitis flares. Liver cirrhosis, more cycles of TACE, HBV DNA negativity, a lower Cancer of the Liver Italian Program score, non-metastasis and no hepatitis flares were protective factors for PFS. Prophylactic lamivudine demonstrated similar efficacy as entecavir. Conclusions: Prophylactic agents are efficacious for prevention of HBV reactivation in HCC patients receiving TACE. Achievement of undetectable HBV DNA levels displayed a significant capability in improving PFS. Moreover, persistent tumor residual lesions, positive HBV DNA and hepatitis B flares might be causes of tumor progression in these patients.Keywords
This publication has 24 references indexed in Scilit:
- Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinomaLiver International, 2013
- Clinical Prediction of Failure of Lamivudine Prophylaxis for Hepatitis B Virus-Infected Patients Undergoing Cytotoxic Chemotherapy for MalignancyAntimicrobial Agents and Chemotherapy, 2012
- Liver Fibrosis and Five Year Survival of Hepatocellular Cancer Cases Undergoing Transcatheter Arterial Chemo Embolization Using Small DosesAsian Pacific Journal of Cancer Prevention, 2012
- Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centreHPB, 2012
- Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2011
- Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceHepatology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolizationHepatology, 2006
- Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinomaJournal of Hepatology, 2004